Data from EMA (European Medicines Agency) - Curated by Toby Galbraith - Last updated 29 September 2017

Indication(s)

Ucedane is indicated in treatment of hyperammonaemia due to N-acetylglutamate synthase primary deficiency.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fabry Disease

Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A

Visit Fabry Disease

Obesity

Learn about the complex factors influencing development of obesity.

Visit Obesity

Related Content

More information

Category Value
Agency product number EMEA/H/C/004019
Orphan designation No
Date First Approved 23-06-2017
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder

Lucane Pharma